Norovirus infection future or investigational therapies: Difference between revisions
m (Changes made per Mahshid's request) |
|||
| Line 4: | Line 4: | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
==Overview== | |||
Clinically approved vaccines are to be investigated for the norovirus infection. | |||
==Future or Investigational Therapies== | |||
A significant limitation to the event of effective control measures has been the lack of a completely permissive cell culture system and little animal model for human noroviruses. Up until now, numerous developments has taken place, yet a licensed vaccine or clinically approved antiviral remains elusive. It would be invaluable to develop an in vitro culture system and an animal model that recapitulates all aspects of the infection as it is in humans. This remains a high priority, as it gives us a much better understanding of the correlates of protection and will enable better vaccine design, eventually leading to the development of a broadly protective vaccine for at least particularly vulnerable or regularly exposed individuals. Until then, effective quarantine and deployment of hygiene measures will help control norovirus outbreaks and minimize its impact on human health.<ref name="pmid24199805">{{cite journal| author=Arias A, Emmott E, Vashist S, Goodfellow I| title=Progress towards the prevention and treatment of norovirus infections. | journal=Future Microbiol | year= 2013 | volume= 8 | issue= 11 | pages= 1475-87 | pmid=24199805 | doi=10.2217/fmb.13.109 | pmc=3904215 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24199805 }} </ref> | |||
== References == | == References == | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 16:51, 28 January 2021
|
Norovirus infection Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Norovirus infection future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Norovirus infection future or investigational therapies |
|
FDA on Norovirus infection future or investigational therapies |
|
CDC on Norovirus infection future or investigational therapies |
|
Norovirus infection future or investigational therapies in the news |
|
Blogs on Norovirus infection future or investigational therapies |
|
Risk calculators and risk factors for Norovirus infection future or investigational therapies |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Clinically approved vaccines are to be investigated for the norovirus infection.
Future or Investigational Therapies
A significant limitation to the event of effective control measures has been the lack of a completely permissive cell culture system and little animal model for human noroviruses. Up until now, numerous developments has taken place, yet a licensed vaccine or clinically approved antiviral remains elusive. It would be invaluable to develop an in vitro culture system and an animal model that recapitulates all aspects of the infection as it is in humans. This remains a high priority, as it gives us a much better understanding of the correlates of protection and will enable better vaccine design, eventually leading to the development of a broadly protective vaccine for at least particularly vulnerable or regularly exposed individuals. Until then, effective quarantine and deployment of hygiene measures will help control norovirus outbreaks and minimize its impact on human health.[1]
References
- ↑ Arias A, Emmott E, Vashist S, Goodfellow I (2013). "Progress towards the prevention and treatment of norovirus infections". Future Microbiol. 8 (11): 1475–87. doi:10.2217/fmb.13.109. PMC 3904215. PMID 24199805.